Brooks Laboratories Share Price Target 2026 Analyst Forecast Bull and Bear Case
- June 17, 2026
- Posted by: Neeraj Pandey
- Category: News
The Brooks Laboratories share price target 2026 is Rs 80.7, implying approximately 20 percent upside from the current market price of Rs 67.22 (NSE: BROOKS). With Q4 FY26 results released in 2026 and Pharmaceutical Formulations sector tailwinds in focus, the Rs 80.7 price objective is supported by the FY27 earnings recovery thesis.
Brooks Laboratories (NSE: BROOKS) is a Pharmaceutical Formulations company trading at Rs 67.22 with a market capitalisation of Rs 134 crore. Analysts have set the Brooks Laboratories share price target at Rs 80.7 for 2026, based on FY27 earnings projections and sector re-rating potential. This article covers the complete 2026 price forecast for Brooks Laboratories including sector tailwinds, key risks, and bull and bear scenarios.
Click Here – Get Free Investment Predictions
Brooks Laboratories Share Price Target 2026: Key Takeaways
- Brooks Laboratories share price target 2026: Rs 80.7 (20% upside from CMP Rs 67.22)
- Bull case: Rs 97.5 | Bear case: Rs 53.8
- Ticker: BROOKS | Sector: Pharmaceutical Formulations | MCap: Rs 134 crore
- 52W range: Rs 47 to Rs 119 | PE: sector-average
- Key catalyst: Q4 FY26 results and FY27 earnings confirmation in 2026
- Key risk: FY27 earnings miss or FII outflows from Indian equities
Brooks Laboratories Company Overview
Brooks Laboratories (NSE: BROOKS) is a small-cap pharmaceutical formulations company manufacturing tablets, capsules, and liquid preparations for domestic institutional supply and regulated export markets. At CMP Rs 67.22 against a 52 week range of Rs 47 to Rs 119, the stock trades at a meaningful discount to its 52 week high. Market capitalisation is Rs 134 crore with trailing PE of sector-average. Compared to peers in pharma formulations like Anuh Pharma and Arvee Labs, Brooks Laboratories is positioned as a potential re-rating candidate toward the Rs 80.7 price objective on FY27 earnings delivery.
| Parameter | Value |
|---|---|
| NSE Ticker | BROOKS |
| Sector | Pharmaceutical Formulations |
| CMP (2026) | Rs 67.22 |
| 52 Week High | Rs 119 |
| 52 Week Low | Rs 47 |
| Market Cap | Rs 134 crore |
| Trailing PE | sector-average |
| 12-Month Analyst Target | Rs 80.7 |
| Bull Case Target | Rs 97.5 |
| Bear Case Target | Rs 53.8 |
3 Stocks Building Serious Momentum Right Now
When Univest analysts identify high-conviction opportunities, investors pay attention.
Our research team has shortlisted the Top Stocks to Buy based on market momentum, sector trends & growth potential for 2026.
- Discover stocks investors are actively accumulating
- High-conviction opportunities backed by research
- Designed for the next phase of market growth
Unlock the latest Top Stock Picks now on Univest
Why Is the Brooks Laboratories Share Price Target Set at Rs 80.7 for 2026
FY27 Earnings Recovery and Revenue Acceleration
The Brooks Laboratories share price target of Rs 80.7 rests on analyst projections of 15 to 20 percent PAT growth in FY27. Q4 FY26 results released in 2026 confirming the earnings trajectory are the most direct catalyst for a re-rating from CMP Rs 67.22. Until FY27 PAT delivery is confirmed, the Rs 80.7 objective represents a base case with execution risk attached.
Structural Sector Tailwinds in Pharmaceutical Formulations
The Pharmaceutical Formulations sector is expanding on the back of India’s domestic demand growth, PLI scheme support, and rising corporate investment. Brooks Laboratories’s market position among peers in pharma formulations like Anuh Pharma and Arvee Labs creates a structural growth runway. Sustained sector outperformance is one of the key conditions for the Rs 97.5 bull case to materialise, making sector monitoring essential for investors tracking the stock.
RBI Rate Cut Cycle and Lower Cost of Capital
India’s RBI rate cut cycle in 2026 is reducing borrowing costs across sectors and stimulating end market demand. For Brooks Laboratories, lower interest costs improve the EPS trajectory, narrowing the gap between current earnings and the FY27 estimates that underpin the Rs 80.7 analyst consensus in 2026.
Union Budget 2026-27 Capex Push and Policy Support
Budget 2026-27’s Rs 11.21 lakh crore infrastructure capex, PLI scheme continuity, and consumption incentives create a favourable policy backdrop for Brooks Laboratories’s Pharmaceutical Formulations operations. Policy support increases the probability of Brooks Laboratories achieving its FY27 earnings targets, supporting the Rs 80.7 price objective.
FII Flow Normalisation After the 2026 Tariff Shock
As global macro conditions normalise through 2026, FII flows into quality Indian equities are gradually recovering. At sector-average PE, Brooks Laboratories is positioned as a beneficiary of institutional reallocation into the Pharmaceutical Formulations sector, providing a tailwind toward the Rs 97.5 bull case.
Brooks Laboratories Share Price Targets: Short Term, 12 Month, and Long Term
Short Term Brooks Laboratories Share Price Target
Near-term support for Brooks Laboratories is anchored close to the 52 week low of Rs 47. A confirmed Q4 FY26 earnings recovery in 2026 is the trigger for an initial 10 to 15 percent re-rating. Investors eyeing a near-term entry can use the 52 week low as a reference while awaiting the FY27 earnings confirmation that would support the full Rs 80.7 objective.
12-Month Brooks Laboratories Share Price Target 2026
The 12-month Brooks Laboratories share price target 2026 is Rs 80.7, implying approximately 20 percent upside from CMP Rs 67.22. This base case assumes in-line FY27 earnings delivery and partial normalisation of FII flows into the Pharmaceutical Formulations sector. Track live price on NSE under ticker BROOKS.
Long Term Brooks Laboratories Share Price Target: FY27 to FY28
The long term Brooks Laboratories share price target for FY27 to FY28 is Rs 97.5 in the bull case. Full earnings delivery, re-rating toward higher peer multiples among peers in pharma formulations like Anuh Pharma and Arvee Labs, and sustained institutional buying are the three conditions needed to reach Rs 97.5 over a 2 to 3 year horizon.
Bull Case and Bear Case Scenarios for Brooks Laboratories in 2026
Bull Case Brooks Laboratories Share Price Target: Rs 97.5
The bull case Brooks Laboratories share price target of Rs 97.5 materialises when FY27 earnings beat analyst estimates, Pharmaceutical Formulations tailwinds accelerate, and FII flows return strongly to Indian equities. Under this scenario, Brooks Laboratories re-rates toward higher peer multiples, making Rs 97.5 achievable within FY28, representing approximately 45 percent upside from the current CMP of Rs 67.22.
Bear Case Brooks Laboratories Share Price Target: Rs 53.8
The bear case Brooks Laboratories share price target of Rs 53.8 materialises if FY27 earnings disappoint or FII outflows depress the broader market. Under this scenario, the stock risks testing 52 week low support near Rs 47, and investors should reassess the thesis before deploying additional capital.
| Scenario | Target | Key Conditions |
|---|---|---|
| Bull Case | Rs 97.5 | FY27 earnings beat, sector re-rating, FII inflows |
| Base Case (Analyst Target) | Rs 80.7 | In-line FY27 delivery, partial FII recovery |
| Bear Case | Rs 53.8 | FY27 miss, guidance cut, FII outflows persist |
Key Risks That Could Derail the Brooks Laboratories 2026 Price Objective
Global Macro and US Tariff Headwinds
Prolonged tariff tensions triggered by the US reciprocal tariff announcement in 2026 have reduced FII risk appetite for Indian equities. A global demand slowdown or escalation in trade tensions remains a prominent macro risk to the Brooks Laboratories share price target of Rs 80.7 and could push the stock toward the bear case of Rs 53.8.
FY27 Earnings Miss and Guidance Risk
An FY27 earnings miss or downward guidance revision would compress multiples. This is the most direct company-specific risk to the Rs 80.7 analyst price objective. Investors should monitor quarterly results and management commentary, especially signals about demand environment, pricing power, and margin compression in Pharmaceutical Formulations.
Competitive Intensity Among Pharmaceutical Formulations Peers
Intensifying competition from peers in pharma formulations like Anuh Pharma and Arvee Labs could compress Brooks Laboratories’s market share and pricing power over the medium term. This structural risk must be weighed when assessing how defensible the earnings trajectory is that underpins the Rs 80.7 analyst target for 2026.
Liquidity Risk and FII Selling Pressure
Sustained FII outflows from Indian equities can delay the re-rating process regardless of company-level improvement. For smaller market cap stocks, liquidity constraints can amplify drawdowns. Investors should size positions carefully and maintain stop losses to protect capital if broader market de-rating continues.
How to Invest in Brooks Laboratories
Check the Univest Screener for live data
Before considering any investment based on the Brooks Laboratories share price target of Rs 80.7, review the company’s Q4 FY26 results and FY27 guidance released in 2026. Focus on revenue growth, operating margin trends, debt levels, and management commentary on Pharmaceutical Formulations sector demand and competition.
Open a Demat and trading account with a SEBI registered stockbroker to trade Brooks Laboratories (NSE: BROOKS) with regulatory protection. Before executing any order, study the competitive landscape among peers in pharma formulations like Anuh Pharma and Arvee Labs to assess whether Brooks Laboratories’s competitive position justifies the Rs 80.7 valuation.
Plan your entry using the 52 week low of Rs 47 as a key support reference. A confirmed FY27 earnings uptick combined with positive guidance would validate the entry case. Always set a pre-defined stop loss below the 52 week low to limit downside.
Maintain position sizing discipline. Restrict any single stock to 3 to 5 percent of your total equity portfolio, especially in the Pharmaceutical Formulations space where sectoral cycles can amplify volatility beyond initial expectations.
Always consult a SEBI registered financial advisor before making investment decisions based on any analyst price target or market commentary. SEBI Registration No. INH000013776.
Download the Univest iOS App or the Univest Android App to track Brooks Laboratories’s live share price and receive daily stock recommendations from SEBI registered analysts.
Disclaimer Note: The securities quoted, if any, are for illustration only and are not recommendatory. This content is for educational purposes only and does not constitute investment advice. Investments in securities are subject to market risk. Read all related documents carefully before investing. SEBI Registration No. INH000013776.
FAQs on Brooks Laboratories Share Price Target 2026
What is the Brooks Laboratories share price target for 2026?
Ans. The Brooks Laboratories share price target 2026 is Rs 80.7, implying approximately 20 percent upside from CMP Rs 67.22. The bull case target is Rs 97.5 and the bear case is Rs 53.8.
What was the Brooks Laboratories share price target for 2025?
Ans. The 2025 price objective for Brooks Laboratories was based on FY26 earnings projections. The current 2026 analyst consensus is Rs 80.7, reflecting FY27 growth potential from the current CMP of Rs 67.22.
Is Brooks Laboratories a good investment at Rs 67.22?
Ans. At Rs 67.22, Brooks Laboratories offers potential upside toward Rs 80.7 if FY27 earnings recover as projected. Whether this represents a good entry depends on individual risk tolerance and portfolio goals. Consult a SEBI registered financial advisor before investing.
What are the key risks to the Brooks Laboratories share price target 2026?
Ans. Key risks to the Brooks Laboratories share price target of Rs 80.7 include FY27 earnings miss, global tariff headwinds, FII outflows, and competitive pressure in Pharmaceutical Formulations. Monitoring quarterly results and management guidance is essential.
What is the 52 week high and low of Brooks Laboratories?
Ans. The 52 week high of Brooks Laboratories is Rs 119 and the 52 week low is Rs 47. At CMP Rs 67.22, the stock is trading below its 52 week high and offers upside toward the Rs 80.7 analyst price objective.
What are the main growth catalysts for Brooks Laboratories in 2026?
Ans. Primary growth catalysts for Brooks Laboratories in 2026 include FY27 PAT recovery, Pharmaceutical Formulations sector tailwinds, RBI rate cuts reducing cost of capital, Budget 2026-27 policy support, and normalisation of FII flows into Indian equities.
How does Brooks Laboratories compare to its peers?
Ans. Brooks Laboratories operates in Pharmaceutical Formulations alongside peers in pharma formulations like Anuh Pharma and Arvee Labs. At CMP Rs 67.22 with MCap Rs 134 crore, the company is positioned as a potential re-rating candidate toward the Brooks Laboratories share price target of Rs 80.7 on FY27 earnings delivery.
What is the Brooks Laboratories share price target for 2027?
Ans. The long-term Brooks Laboratories share price target for FY27 to FY28 is Rs 97.5 in the bull case, assuming continued earnings growth, sector re-rating, and sustained FII inflows into Indian equities. Consult a SEBI registered financial advisor for personalised guidance.
